IDEXX Laboratories, Inc. vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.45 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is the larger of the two by market cap, and Vanguard Sht-Term Inflation-Protected Sec Idx ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 91 Days on average.
| IDXX | VTIP | |
|---|---|---|
Market Cap | $40.43B | $73.20B |
Volume | 692,164 | 2,511,360 |
Sector | Health | — |
52-Week High | $766.68 | $50.46 |
52-Week Low | $504.70 | $48.38 |
Typical Hold Time | 46 Days | 91 Days |
Enterprise Value | $41.32B | — |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
VTIP (Vanguard Short-Term Inflation-Protected Securities ETF) trades at $48.46, showing minimal daily movement with a 0.08% gain. Technical indicators present mixed signals with a bearish overall trend but bullish oscillators. The ETF focuses on short-duration TIPS to hedge inflation while minimizing interest rate sensitivity. Recent institutional buying activity includes NewEdge Advisors increasing their position by 45.5% in Q2 2026.
The ETF offers defensive positioning amid persistent inflation above the Fed's 2% target for 65 consecutive months. While providing inflation protection with reduced duration risk, VTIP faces headwinds from potential Fed policy shifts and competition from other TIPS vehicles. Real yields at multi-decade highs create attractive entry points for inflation-sensitive allocations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →